Navigation Links
CardioDynamics Announces Investors Retain $5.25 Million 8% Convertible Debt Securities
Date:1/14/2009

Maturity Date Remains April 11, 2011, with $8.05 Conversion Price

SAN DIEGO, Jan. 14 /PRNewswire-FirstCall/ -- CardioDynamics (Nasdaq: CDIC), the innovator and leader of BioZ(R) impedance cardiography (ICG) technology, today announced that the Company's note holders had not exercised their "put" rights regarding the $5.25 million, 8% subordinated convertible debt securities. The terms of the notes provided an option under which the holders had an opportunity to elect, in January 2009, to be repaid in April 2009. Since the put option expired unexercised, the maturity date for the debt remains April 11, 2011. The convertible notes carry an 8% interest rate, payable in cash semi-annually with a conversion price of $8.05 per share.

"We are pleased that our debt holders have chosen to remain invested in CardioDynamics," stated Michael K. Perry, Chief Executive Officer. "We have seen continued improvement in our operating performance with seven consecutive quarters of revenue growth and an 83% reduction in operating loss over the past two years. Our objective for 2009 is to continue the positive growth trend and to achieve cash flow break-even for the full fiscal year."

About CardioDynamics:

CardioDynamics (Nasdaq: CDIC), the ICG Company, is the innovator and leader of an important medical technology called BioZ(R) Impedance Cardiography (ICG). The Company develops, manufactures and markets noninvasive BioZ(R) ICG products and medical device electrodes. The Company's BioZ(R) ICG Systems are being used by physicians around the world to help battle the number one killer of men and women -- cardiovascular disease. Partners include GE Healthcare, Philips Medical Systems, and Mindray. For additional information, please refer to the company's Web site at www.cdic.com.

Forward-Looking (Safe Harbor) Statement:

Except for the historical and factual information contained herein, this press release contains forward-looking statements, the accuracy of which is necessarily subject to uncertainties and risks including the Company's sole dependence on the BioZ(R) product line, positive growth trends, achievement of cash flow break-even and various uncertainties characteristic of early growth companies, as well as other risks detailed in the Company's filings with the SEC, including its 2007 Form 10-K. The Company does not undertake to update the disclosures contained in this press release.


'/>"/>
SOURCE CardioDynamics
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. CardioDynamics Reports Second Fiscal Quarter 2008 Results, 18% Revenue Increase for First Half 2008
2. CardioDynamics Announces Second Quarter 2008 Conference Call and Webcast
3. CardioDynamics Announces Significant ICG Study with Nearly Three Times the National Average Blood Pressure Control Rates at the American Society for Hypertension Annual Scientific Meeting
4. CardioDynamics Reports 22% Revenue Growth in First Quarter 2008
5. CardioDynamics Board of Directors Proposes Reverse Split 1:7 of Companys Shares
6. CardioDynamics Reports Fourth Quarter and Fiscal 2007 Results with 10% Revenue Growth in 2007
7. CardioDynamics Announces Strategic Alliance With Leading Medical Equipment Manufacturer in India
8. CardioDynamics Announces Third Quarter 2007 Conference Call and Webcast
9. BD Announces Live Webcast of First Fiscal Quarter Earnings Conference Call
10. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Fourth Quarter and Full-Year 2008 Results
11. Environmental Tectonics Corporation Announces Third Quarter and Year To Date Fiscal 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica ... Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs ... Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, ...
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... ... ... of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum Wage’ ... 2020 and then adjusting it yearly to increase at the same rate as the median ... floor does not erode again, and make future increases more predictable. , The company is ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... and INDIANAPOLIS , June 23, ... a Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, ... winners, announced today online at www.diabetesscholars.org by ... 1 diabetes stand in the way of academic and ... the Foundation,s scholarship program since 2012, and continues to ...
(Date:6/23/2016)... PRINCETON, N.J. , June 23, 2016  Guerbet ... of Premier Inc.,s Supplier Horizon Award . ... this year, Guerbet was recognized for its support of ... value creation through clinical excellence, and commitment to lower ... delighted to receive this recognition of our outstanding customer ...
(Date:6/23/2016)... FRANKLIN, Tenn. , June 23, 2016 ... for automating, integrating and transforming the patient ... launch of several innovative new products and ... depth of its revenue cycle offerings. These ... establish more efficient workflows, remain compliant in ...
Breaking Medicine Technology: